Gilead was supposed to have a slam dunk today with FDA advisory panel for adefovir(HIV/Hepatitis Tx). Denied 13-1. There are no sure things. Adeforvir had fast-track status, CEO was promising the world. No sure things in this world. November 17th will tell the story. I was surprised there wasn't more press surruonding the last ophthamology conference. Will deifinitey wait till after the advisory panel meets to add to my position.
ttotoole summed up what's going on here: down in sympathy with Gilead getting hammered. The concern with Gilead, by the way, was patient safety, not efficacy, so the stories clearly aren't parallel on any level.
Personally, I'd like to see this thing go lower so I can get in before the FDA.